Antibiotics for treatment of resistant gram-positive coccal infections

被引：8

作者：

Hossam Al-Tatari

Nahed Abdel-Haq

Pimpanada Chearskul

Basim Asmar

机构：

[1] Wayne State University School of Medicine,Carman and Ann Adams Department of Pediatrics

[2] Children's Hospital of Michigan,Division of Infectious Diseases

来源：

The Indian Journal of Pediatrics | 2006年 / 73卷 / 4期

关键词：

Vancomycin; Gram-positive; Bacterial infections; Antibacterial agents;

D O I：

10.1007/BF02825827

中图分类号：

学科分类号：

摘要：

Vancomycin is considered the workhorse for the treatment of most drug-resistant gram-positive bacterial infections. However, concerns have been raised regarding the increasing rates of vancomycin-resistant enterococci and the clinical shortcomings of vancomycin in the treatment of invasiveStaphylococcus aureus infections. Resources have been committed to the development of antimicrobial agents with activity against these organisms. This review will focus on the newer antibacterial agents that have been developed for the treatment of resistant gram-positive pathogens. Included in this review are the agents: quinupristin-dalfopristin, linezolid, daptomycin, telithromycin, and tigecycline.

引用

页码：323 / 334

页数：11

共 346 条

[1]

Kirst HA(1998)Historical yearly usage of vancomycin Antimicrobial Agents & Chemotherapy 42 1303-1304

[2]

Thompson DG(1994)Emergence of vancomycin tolerance in MMWR Morb Mortal Wkly Rep 43 1-80

[3]

Nicas TI(1999) [see comments] Nature 399 590-593

[4]

Novak R(1999)Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. [comment] New England Journal of Medicine 340 493-501

[5]

Henriques B(2002)Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis [see comments] MMWR—Morbidity & Mortality Weekly Report 51 565-567

[6]

Charpentier E(1991)Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients Annals of Internal Medicine 115 674-680

[7]

Normark S(1999)Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms Journal of Infectious Diseases 179 1157-1161

[8]

Tuomanen E(1999)Antimicrobial activity of quinupristin-dalfopristin (RP 59500, synercid)tested against over 28,000 recent clinical isolates from 200 medical enters in the United States and Canada Clinical Infectious Diseases 29 1171-1177

[9]

Smith TL(1998)The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group Diagn Microbial Infect Dis 31 437-451

[10]

Pearson ML(1999)Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicoated studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group J Antimicrob Chemotherapy 44 251-261

← 1 2 3 4 5 6 7 8 9 10 →